Rivoglitazone

DRUG2 trials

Sponsors

Daiichi Sankyo

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

CompletedNCT00143520

Daiichi SankyoType 2 Diabetes

Start: 2004-12-31End: 2005-12-31Updated: 2021-05-10

Phase 3

Study of Rivoglitazone in Type 2 Diabetes Mellitus

CompletedNCT00484198

Daiichi SankyoType 2 Diabetes Mellitus

Start: 2007-04-23End: 2009-02-12Updated: 2021-07-27

Related Papers

A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.

2010-06-0111 citations